- Home
- UFCS vs CELC Comparison
UFCS vs CELC Comparison
Compare UFCS & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UFCS
- CELC
- Stock Information
- Founded
- UFCS 1946
- CELC 2011
- Country
- UFCS United States
- CELC United States
- Employees
- UFCS N/A
- CELC N/A
- Industry
- UFCS Property-Casualty Insurers
- CELC Medical Specialities
- Sector
- UFCS Finance
- CELC Health Care
- Exchange
- UFCS Nasdaq
- CELC Nasdaq
- Market Cap
- UFCS 642.7M
- CELC 594.7M
- IPO Year
- UFCS N/A
- CELC 2017
- Fundamental
- Price
- UFCS $29.21
- CELC $12.83
- Analyst Decision
- UFCS Hold
- CELC Strong Buy
- Analyst Count
- UFCS 1
- CELC 6
- Target Price
- UFCS $26.00
- CELC $29.17
- AVG Volume (30 Days)
- UFCS 114.1K
- CELC 273.4K
- Earning Date
- UFCS 11-05-2024
- CELC 11-14-2024
- Dividend Yield
- UFCS 2.34%
- CELC N/A
- EPS Growth
- UFCS N/A
- CELC N/A
- EPS
- UFCS 1.94
- CELC N/A
- Revenue
- UFCS $1,207,451,000.00
- CELC N/A
- Revenue This Year
- UFCS N/A
- CELC N/A
- Revenue Next Year
- UFCS $9.19
- CELC N/A
- P/E Ratio
- UFCS $14.06
- CELC N/A
- Revenue Growth
- UFCS 10.95
- CELC N/A
- 52 Week Low
- UFCS $18.04
- CELC $11.51
- 52 Week High
- UFCS $27.69
- CELC $22.19
- Technical
- Relative Strength Index (RSI)
- UFCS 80.36
- CELC 31.53
- Support Level
- UFCS $24.62
- CELC $11.51
- Resistance Level
- UFCS $27.69
- CELC $16.14
- Average True Range (ATR)
- UFCS 0.98
- CELC 1.00
- MACD
- UFCS 0.49
- CELC -0.36
- Stochastic Oscillator
- UFCS 99.83
- CELC 25.23
About UFCS United Fire Group Inc.
United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.